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ABSTRACT
This study aimed to evaluate the pace of curing process and body weight recovery of pulmonary 
tuberculosis (Tb) patients receiving propolis supplementation. This study was a randomized controlled 
trial conducted on 50 pulmonary Tb patients that were assigned into three groups as follows: receiving 
standard-dose antituberculosis drugs (ATDs) + 20 drops of placebo propolis (P0); receiving standard-
dose ATDs + 20 drops of propolis with concentration of 6% (P1); and receiving standard-dose ATDs + 
20 drops of propolis with concentration of 30% (P2). The results showed that the mean time ratio needed 
for sputum smear conversion to negative present of acid resitant bacteria in P0, P1 and P2 groups were 
weeks 10, 8 and 5, respectively. In the second week, mean body weight of P0 and P1 groups decreased 
by 2.4% and 0.2%, respectively. In contrast, the mean body weight in P2 group increased by 1.5% 
(p<0.05; Mann-Whitney test). In the same week, mean body mass index (BMI) of P0 and P1 groups 
decreased by 1.6 and 0.1, respectively. Conversely, the mean BMI of P2 group increased by 0.3. The 
changes were significantly different (p<0.05). The results conclusively indicated that supplementation 
of 20 drops of propolis with a concentration of 30% as an adjuvant to standard ATDs for the treatment of 
pulmonary Tb patients was beneficial to accelerate treatment effect and body weight recovery.
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INTRODUCTION
Tuberculosis (Tb) is a global infectious 
disease problem and becoming the second lead-
ing cause of death after HIV/AIDS infection. 
Indonesia is ranked 2nd out of 30 high burden 
countries in the world (WHO 2016). Tb treat-
ment and cure requires regular consumption of 
anti-tuberculosis drugs (ATDs) every day with-
out interruption for a substantially long term peri-
od. One of the problems faced in the use of ATDs 
to date is its hepatotoxic properties (Chowdhury 
et al. 2006; WHO 2013). The hepatotoxic effects 
of ATDs can cause decrease in appetite, nausea, 
dizziness, insomnia, fever and weight loss (Ke-
menkes 2009; Sudarsanam & Tharyan 2014; Sari 
et al. 2014). These hepatotoxic effects further 
cause decline in nutritional status of the patients, 
whereas good nutritional status strongly supports 
cure (Semba & Bloem 2001). Thus, the provision 
of hepatoprotective materials is expected to re-
duce hepatotoxic effects that eventually may re-
store body weight (BW) faster. 
Other studies conducted by Bhadauria et 
al. (2007), Hashmi et al. (2013) and Cevik et al. 
(2012) showed that propolis has a hepatoprotec-
tive properties, characterized by its ability to de-
crease SGPT and SGOT approaching the normal 
values and protection from liver damage in mice 
models. Pranandaru et al. (2011) found that pro-
polis had the ability to fight Tb infection charac-
terized by the sputum conversion--where acid-re-
sistant bacteria (ARB) in the acid stained sputum 
smear is found negative--in Tb patients. Wahyu-
nitisari et al. (2006) stated that altough propolis’s 
ability to fight Tb infection was limited, it has 
several advantages when supplemented for Tb 
treatment such as it does not stimulate Mycobac-
terium tuberculosis to develop resistance and is 
more compatible with normal intestinal flora of 
Tb patients. Therefore, propolis has a potential to 
help overcome Tb problem in Indonesia. A num-
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ber of studies have also revealed that propolis 
synergizes with ampicillin, gentamycin and strep-
tomycin to eradicate M. tuberculosis (Scazzoc-
chio et al. 2006); synergizes with streptomycin, 
rifampicin, isoniazid and ethambutol (Scheller et 
al. 1999); as well as synergizes with streptomycin 
and cloxacyllin (Krol et al. 1993). The synergy 
of propolis with antibiotics commonly use for Tb 
treatment, lead to potential acceleration of the 
healing process. However, a study from Halim 
et al. (2012) suggested that Indonesian propolis 
had a potential good efficacy, thus needs further 
study.      
Based on the above reasoning, propolis 
with its dual ability (as hepatoprotector and also 
fighting M. tuberculosis infection) has a potential 
properties to accelerate the cure process and BW 
recovery of pulmonary Tb patients. Thus, this 
study aimed to evaluate the ability of propolis to 
accelerate the cure process and BW recovery of 
pulmonary Tb patients. 
METHODS
Design, location, and time
The design used was randomized con-
trolled trial, consisting of one positive control 
group and two treatment groups. The study was 
conducted in 24 public health centers (Puskes-
mas) in Bogor City, which lasted from December 
1, 2015 to November 29, 2016. ATDs’ packages 
were obtained from Puskesmas. Liquid propolis 
used was derived from the extraction of Geniotri-
gona incisa bee propolis from South Sulawesi 
that had passed a series of screening process. 
Sampling
A total of 50 Tb patients were determined 
according to sample size table for controlled clin-
ical trial with α of 0.05 and 80% power, result-
ing in 13 subjects per group (Chow et al. 2008). 
The subjects were recruited from all Puskesmas 
in Bogor City with a) inclusion criteria: Tb pa-
tients, adults aged 15-60 years, were willing to 
participate in the study by signing informed con-
sent; and b) exclusion criteria: recurrent Tb pa-
tients, smoking, had hepatitis or other diseases 
that interfered the study, alcohol drinkers, preg-
nant, breastfeeding, using contraception, taking 
other drugs/herbal medicine/supplements. The 
subjects’ age criterion was based on National 
Guidelines for Tuberculosis Control (Kemen-
kes 2014); i.e. adult patients (15 years or older). 
However, it was stated in the guidelines that adult 
patients aged over 60 years old were not able to 
tolerate drug dose of >500 mg/day, thereby the 
subjects in this study were adult patients aged 
15-60 years. Considering that the age range was 
too wide and it had the potential to produce dif-
ferent responses to the intervention, the adult pa-
tients in this study were divided into two groups 
based on the age groupings by Ministry of Health 
(Kemenkes) (2009), namely adolescents (15-25 
years) and adults (26-60 years). 
The research consisted of one positive 
control group and two treatment groups (Table 
1). Each subject received 6-month intervention 
according to National Guidelines for Tubercu-
losis Control (Kemenkes 2014). Permuted block 
randomization was used to obtain subjects with 
equal sex and age groups (Chow & Liu 2004). In-
tervention and analysis were double-blinded (not 
known by the subjects, researchers, assistant or 
analyst). 
Each group (P0, P1 and P2) had an equal 
number of subjects, either based on sex (male 
and female) or age groups (adolescents aged 15-
25 years and adults aged 26-60 years), by using 
permuted block randomization. The blocks in 
each group were made based on sex (male and 
female) and age groups (adolescents and adults). 
Thus, each group consisted of four blocks; i.e. 
1) male-adolescents, 2) male-adults, 3) female-
adolescents and 4) female-adults. Each time a 
subject was obtained, the placement in the group 
was done by taking a roll of paper containing P0, 
P1 and P2 codes. The subjects were placed ac-
cording the group code drawn. Placement of the 
subjects was repeated if there was a sequential 
placement more than once in the group and the 
block.
Group Intensive phase every day for 8 weeks RHZE (150/75/400/275)+ Propolis
Continuation phase 3 times a week for 16 weeks
RH (150/150) + Propolis
P0 4 4FDC tablets + 20 drops of placebo propolis 4 2FDC tablets + 20 drops of placebo propolis
P1 4 4FDC tablets + 20 drops of 6% propolis 4 2FDC tablets + 20 drops of 6% propolis
P2 4 4FDC tablets + 20 drops of 30% propolis 4 2FDC tablets + 20 drops of 30% propolis
Description: FDC = Fixed-Dose Combination. The dose of ATDs used was the dosage for adult patients according to the Na-
                     tional Guidelines for Tuberculosis Control (Kemenkes 2014).
Table 1. Description of control and treatment provision on the subjects
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Recruitment and screening of prospective 
subjects were performed by Tb program officers 
in all Puskesmas in Bogor City. The screening 
was conducted by listing, checking the sputum 
and interviewing the visitors in Tb eradication 
program section in Puskesmas. If the visitors met 
the inclusion and exclusion criteria, they were 
determined as prospective subjects. Prospective 
subjects were then offered to be research subjects. 
If they agreed, the Tb program officers in Puskes-
mas reported it to the researchers. Subsequently, 
the signing of informed consent was done by the 
researchers and the subjects, and continued with 
baseline data collection immediately before the 
intervention was conducted. 
Distribution of ATDs to the subjects was 
conducted by Puskesmas’s Tb program officers. 
Meanwhile, propolis distribution was done by the 
research assistant who also acted as a drug con-
sumption supervisor (DCS). During the intensive 
treatment period (the first two months), the DCS 
visited the subjects every day to ensure that they 
actually consumed the ATDs and propolis. Du-
ring the continuation treatment period (the 3rd-6th 
months), the DCS visited three times a week. 
This study had obtained ethical approval 
from Health Research Ethics Committee, Faculty 
of Medicine of University of Indonesia number: 
1036/UN2.F1/ETIK/2015.
Data collection
The observation parameters covered: 1) M. 
tuberculosis acid-resistant bacteria (ARB) that 
included positive 3, positive 2, positive 1 and 
negative in ARB; 2) anthropometric measure-
ments: body height (measured once at the begin-
ning), BW and body mass index (BMI). The data 
were collected in week 0 (before intervention as 
baseline data), every week during intensive treat-
ment phase in the first two months, and every 
month during continuation treatment phase (from 
the 3rd month to the 6th month).    
The materials used for sputum’s ARB 
analysis (Ziehl-Neelsen stain method) were spu-
tum of the subjects, 70% alcohol, carbol fuchsin, 
3% alcohol, water, 0.3% methylene blue solution, 
0.1% methylene blue solution and oil immersion. 
Meanwhile, the tools used were microscope slide, 
spirit lamp, sterile inoculating loop, staining rack 
and microscope. The tools used for anthropomet-
ric measurements were questionnaires, weight 
scales and height measurement tools.  
Data on sputum’s ARB status were oba-
ined at Puskesmas where subjects were asked to 
bring their collected morning sputum, the sputum 
at the time the patients were in Puskesmas was 
also collected for analysis. Bacteriological col-
lection and analysis of ARB were conducted by 
Puskesmas officers. Body height data were ob-
tained by measuring height of the Tb subjects at 
the beginning of the study using SH-2A height 
measurement tool, and it was performed by the 
Puskesmas officers. BW data were obtained by 
weighing the subjects using Camry EB9005 step-
on scale in their respective homes, which was 
performed by the research assistant. BMI data 
were obtained by dividing the BW (kg) with the 
square of height (m2).  
Data analysis
Sputum’s ARB status data was processed 
and presented descriptively. Kruskal-Wallis test 
was used to analyze mean values of BW and 
BMI, while Mann-Whitney advanced test with 
significance level of 0.05 and 0.1 was used to 
analyze the significance of the difference in mean 
BW and BMI between treatments.
RESULTS AND DISCUSSION
Subjects’ characteristics
The important characteristics of subjects 
that affected the response were sex and age. 
Therefore, this study used permuted block ran-
domization to ensure that each group received 
equal distribution of sex and age resulted in distri-
bution of sex (male-female) between the groups; 
i.e. 50.00%:50.00% in P0 group, 50.00%:50.00% 
in P1 group and 53.33%:46.67% in P2 group. 
Meanwhile, in terms of age, the mean age ob-
tained were 30 years in P0 group, 30.1 years in 
P1 group and 29.3 years in P2 group. Thus, sex 
and age characteristics between groups were rela-
tively equal, thereby the response that emerged 
was the result of the provison of intervention. 
Detailed subjects’ characteristics are presented in 
Table 2. 
Acid resistant bacteria (ARB) conversion
The bacteriological evidence treatment 
success of “cured” of Tb subjects was character-
ized by the occurrence of sputum smear conver-
sion, from sputum smear positive in ARB into 
negative in ARB. The results of baseline spu-
tum’s ARB status analysis (before the interven-
tion) are presented in Figure 1. Based on the fig-
ure, sputum’s ARB status composition of P0 and 
P1 groups were relatively equal. Meanwhile, P2 
group was tend to be more severe, dominated by 
nine Tb subjects (60%) with positive 3 in spu-
tum’s ARB status. 
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The rate of sputum’s ARB conversion pro-
cess in each group was different. In P0 group, 
the conversion of sputum’s ARB started to occur 
in the 6th week on one subject (7.1%). The next 
conversion in sputum’s ARB occurred at weeks 
7, 8, 12 and 24 with conversion accumulation of 
28.6%, 64.3%, 92.9% and 100%, respectively. 
Conversion in sputum’s ARB in P1 began to oc-
cur in the 6th week on one subject (7.1%). The 
subsequent conversion in sputum’s ARB occurred 
at weeks 7, 8 and 12 with conversion accumula-
tion of 35.7%, 78.6% and 100%, respectively. In 
Mahani et al.
P2 group, sputum’s ARB conversion began to oc-
cur in the 3rd week on four subjects (26.7%). The 
next conversion happened at weeks 4, 5, 7 and 12 
with conversion accumulation of 66.7%, 86.7%, 
93.3% and 100%, respectively.
There were differences in conversion rate 
of sputum’s ARB in the three groups; i.e. the 
sputum smear conversion in P2 group occurred 
earlier than the other groups. In the 3rd and 7th 
weeks, conversion of sputum’s ARB in P2 group 
had reached 93.3%. In the same week (the 7th 
week), the sputum’s ARB conversion in P0 and 
P1 groups only reached 28.6% and 35.7% con-
version, respectively. Furthermore, when the data 
was compared to the composition of baseline 
sputum’s ARB status, the P2 group was in fact 
more severe than other groups.  
Based on mean conversion time the heal-
ing of P2 group was the fastest, which was five 
weeks faster than P0 group and three weeks fast-
er than P1 group. Therefore, the order of healing 
process was P2>P2>P0. The differences in heal-
ing rates between groups are presented in Figure 
2.
Table 2. Subjects’ characteristics of the randomization results
Variable
Group
P0 P1 P2
n (%) n (%) n (%)
Initial number (N0) 17 17 16
Drop out 3 (17.64) 3 (17.64) 1 (6.25)
The final number (NA) 14 (82.36) 14 (82.36) 15 (93.75)
Sex (NA)
     Male
     Female
7 (50.00)
7 (50.00)
7 (50.00)
7 (50.00)
8 (53.33)
7 (46.67)
Age range (NA);(years) 15-47 17-55 17-54
Mean age (NA);(years) 30 30.1 29.3
Education (NA)
     Did not have an education
     Dropped out of elementary school
     Graduated from elementary school
     Graduated from junior high school
     Graduated from senior high school
2 (14.29)
1 (7.14)
2 (14.28)
4 (28.57)
5 (35.71)
0 (0.00)
3 (21.43)
3 (21.43)
3 (21.43)
5 (35.71)
0 (0.00)
1 (6.67)
4 (26.67)
7 (46.67)
3 (20.00)
Occupation (NA)
     Civil servant
     Private employee
     Entrepreneur
     Others*
0 (0.00)
3 (21.43)
1 (7.14)
10 (71.43)
0 (0.00)
2 (14.28)
1 (7.14)
11(78.57)
1 (6.67)
1 (6.67)
0 (0.00)
13 (86.67)
Income (IDR); (NA)
     Do not have income
     Less than 1,500,000/month
     1,500,000- <5,000,000/month
2 (14.29)
9 (64.29)
3 (21.43)
0 (0.00)
10 (71.42)
4 (28.57)
0 (0.00)
13 (86.67)
2 (13.33)
Description: *Others=other categories such as casual agricultural laborer, construction worker, etc. P0: ATDs + placebo propo-
                       lis group, P1: ATDs + 6% propolis group, and P2: ATDs + 30% propolis group. All dropped-out (DO) subjects 
                       were found in the first two weeks of intervention because the subjects were known not to take the drugs in one 
                       day, except one subject in P0 group who resigned and one subject in P1 group who was later defined as not Tb 
                       patient by the doctor. 
Figure 1. Bar chart of analysis results of the sub-
        jects’ ARB in P0, P1, and P2 groups 
               before intervention 
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mycobacterial ability. Cantrell et al. (2001) have 
mentioned that compounds of diterpene, triter-
pene and sesquiterpene classes have anti-myco-
bacterial activity, even some of their derivatives 
show anti-tuberculin activity almost similar to 
ATDs. The compounds are found in propolis. To-
reti et al. (2013) have reviewed the compounds 
contained in the propolis that act as antibacterial 
and antibiotic; i.e. flavanones, flavones, phenolic 
acids and esters, prenylated p-coumaric, labdane 
diterpenes, prenylated flavanones, and prenylat-
ed benzophenones. The study results of Katerere 
et al. (2012) have revealed that pinocembrin has 
anti-mycobacterial activity, and the activity of 
this compound is increased when coupled with 
other phytochemicals. 
Body weight (BW)
Body weight is a standard measure of nu-
tritional status and is sensitive to sudden changes 
such as infection and food consumption (Gersh-
win et al. 2004). The patterns of BW changes in 
P0 and P1 groups had similarities, whereas the 
pattern of BW change in P2 group was different. 
The percentages of mean BW changes are pre-
sented in Figure 3.
There was a decrease in BW of the sub-
jects in P0 group until the 4th week. Their weight 
began to recover (equal or higher than baseline 
BW) in the 5th week, with an increase of 0.8%. 
Decreased BW was thought to be caused by 
hepatotoxic effects of ATDs (i.e. nausea, dizzi-
ness and decreased appetite), thus the food in-
take was lower than normal. The data on differ-
ences in food intakes between P0 group (ATDs 
+ placebo propolis) and P2 group (ATDs + 30% 
propolis) in this study have been reported by 
Pranajaya (2017) as presented in Table 3. These 
data showed that nutritional adequacy level of P2 
group was higher than P0 group.
A faster recovery will give significant ben-
efits to the subjects; i.e. nutrient intakes will be 
fully utilized to restore nutritional status, health 
and productivity maintenance, and can be used 
for growth for the subjects who are still in the 
growth period. Nutrient intakes of the subjects 
that had not cured were partially mobilized to 
fight infection. It was seen in the P2 group that 
directly experienced BW and BMI improvements 
since the first week. P1 group took three and four 
weeks to restore BW and BMI. P0 group took 
five weeks to restore BW and had not been able to 
restore the BMI until the end of the intervention. 
Based on the above sputum smear bacte-
riological conversion data, propolis has shown 
good ability to fight M. tuberculosis infection. 
This result is in agreement with the study results 
of Syamsudin et al. (2008) and Pranandaru et al. 
(2011). The result also strengthens the study re-
sults of Scazzocchio et al. (2006), Scheller et al. 
(1999), and Krol et al. (1993) who have suggest-
ed that propolis synergizes with ATDs in fighting 
M. tuberculosis infection. The ability of propolis 
to fight M. tuberculosis is influenced by the active 
components in it, which is known to have anti-
Figure 3. Percentage of mean body weight changes of the subjects in P0, P1 and 
                P2 groups during intervention
Figure 2. Bar chart of ARB conversion rates in- 
                P0, P1, and P2 groups
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Table 3. Mean nutritional adequacy level of the subjects (pulmonary Tb patients) receiving propolis
              supplementation and placebo before and after the intervention
Before 
intervention
After 
intervention Mean change
Placebo group
Energy
Protein
Fat
Carbohydrates
56.6 ± 17.7a
34.4 ± 15.6a
48.8 ± 23.6a
66.0 ± 24.4a
62.3 ± 13.7a
40.9 ± 16.1a
57.9 ± 22.7a
66.5 ± 14.3a
5.7 ± 13.61
6.5 ± 14.91
9.1 ± 27.81
0.6 ± 21.81
Treatment groups
Energy
Protein
Fat
Carbohydrates
52.3 ± 21.8a
31.1 ± 15.6a
48.7 ± 27.7a
59.1 ± 25.3a
65.1 ± 16.1b
48.8 ± 12.0b
61.6 ± 28.1a
68.1 ± 17.9b
12.8 ± 20.71
17.8 ± 13.21
12.9 ± 29.41
9.0 ± 27.21
 Description: 1Different figures in the same column indicate significant differences between groups (p<0.05); adifferent letters
                       in the same row show significant differences between time (p<0.05).
The subjects in the P1 group lost weight 
during the first two weeks. Their weight began to 
recover in the 3rd week with an increase of 0.1%. 
If compared with the changes in BW of P0 group, 
the BW of P1 group recovered two weeks earlier. 
It was allegedly due to the effect of hepatoprotec-
tive activity of propolis so that the hepatotoxic ef-
fects of ATDs decreased which leaded to appetite 
recovery, thereby the BW recovered faster.  
In contrast to the other groups, the P2 group 
did not experience weight loss and immediately 
gained weight from the start of intervention. The 
BW continued to increase until the end of inter-
vention. The increase in BW was proposed as the 
cause of propolis supplementation with a dose 
of 30% that effectively reduced the hepatotoxic 
effects of ATDs. The BW changes shown by all 
groups proved that 30% propolis supplementa-
tion was able to reduce the hepatotoxic effects 
of standard-dose ATDs. The differences in BW 
changes were particularly prominent, observed 
from the 2nd week to the 6th week of intervention. 
Statistically, BW changes in the 2nd week were 
significantly different (p<0.05) (Table 4).
Based on the observation on weight chang-
es, there was a strong indication that intensive 
Response
Model test 
(Kruskal-Wallis) Mann-Whitney advanced test
p Treatment p Description
BWW1-BW0 
difference
0.028*
 
 
P0-P1 0.454 Not significantly different
P0-P2 0.158 Not significantly different
P1-P2 0.029 Significantly different at 5% level
BWW2-BW0 
difference
0.006*
 
 
P0-P1 0.635 Not significantly different
P0-P2 0.002 Significantly different at 5% level
P1-P2 0.023 Significantly different at 5% level
BWW6-BW0 
difference
0.000*
 
 
P0-P1 0.062 Significantly different at 10% level
P0-P2 0.000 Significantly different at 5% level
P1-P2 0.000 Significantly different at 5% level
BWW8-BW0 
difference
0.000*
 
 
P0-P1 0.104 Not significantly different
P0-P2 0.000 Significantly different at 5% level
P1-P2 0.000 Significantly different at 5% level
BWW24-BW0
0.229
 
 
P0-P1 0.804 Not significantly different
P0-P2 0.186 Not significantly different
P1-P2 0.134 Not significantly different
*Significantly different at 5% level.
Table 4. Kruskal-Wallis test and Mann-Whitney advanced test on the difference in mean BW of the         
              subjects at weeks 1, 2, 6, 8 and 24
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use of ATDs caused a decrease in BW through 
the hepatotoxic mechanism. Hepatotoxic effects 
includes decreased in appetite, nausea and diz-
ziness (Sari et al. 2014), thus the food intake de-
creased drastically that led to weight loss. The 
weight recovery was noticeable after entering 
continuation treatment period (the 9th week until 
the 24th week), either in the group not receiving 
propolis supplementation (P0) or the groups re-
ceiving propolis supplementation (P1 and P2). It 
indicated that the subjects could recover from the 
toxic effects of ATDs. Statistically, the mean BW 
in all groups at the end of intervention were not 
significantly different.  
Propolis supplementation in this study pro-
vided additional benefit of liver protection from 
the toxic effects of ATDs, especially in the first 
two weeks of intensive treatment phase. Liver 
protection by the propolis was ultimately useful 
to accelerate the BW recovery of the subjects. 
The results of this study strengthened the study 
results of Bhadauria et al. (2007), Hasmi et al. 
(2013) and Cevik et al. (2012) who stated that 
propolis was hepatoprotective. It was also seen 
that the higher the dosage of propolis supplemen-
tation, the faster and higher the BW recovery is. 
In this study, the BW recovery of the patients in 
P2, P1 and P0 groups occurred at weeks 1, 3, and 
5, respectively. 
Body mass index (BMI)
BMI is one of the adult nutritional status 
indicators. Based on the changes in mean differ-
ence of BMI, P0 group experienced a decrease in 
BMI since the beginning of intervention and had 
not recovered until the end of intervention (24 
weeks). The final BMI remained negative (-0.2). 
The decrease in BMI was very drastic during the 
1st and 2nd weeks (W1 and W2) and it continued 
until the 8th week (W8). In continuation treatment 
period (from the 9th week to the end of interven-
tion), BMI had increased slowly. These data in-
dicated that intensive provision of ATDs could 
suppress the nutritional status of the subjects as 
a result of its hepatotoxic effects. The changes in 
mean BMI are presented in Figure 4.
In the continuation treatment phase (ATDs 
administered only 3 times a week), the strength 
of pressure on nutritional status was also reduced. 
In the P1 group, the decrease in BMI occurred 
during the first three weeks and started to be posi-
tive in the 4th week (0.1). In the 24th week, BMI 
increased by 0.9. When compared to P0 group, 
the decrease in nutritional status in P1 group was 
smaller, and it occurred in shorter duration. It 
means that supplementation of 20 drops of 6% 
propolis in ATDs provide benefits for nutritional 
status recovery of the subjects. 
Unlike the other groups, the P2 group im-
mediately experienced an increase in BMI from 
the beginning of intervention and it continued to 
increase until the end of intervention. In the first 
week, the BMI increased by 0.2. BMI continued 
to increase until the 8th week (W8) and the in-
crease reached 1.2. Therefore, the BMI increased 
by 1.2 during the intensive treatment period. The 
final BMI (W24) reached 1.5. Thus, it could be 
said that the BMI increased only by 0.3 during 
the four months of continuation treatment peri-
od. These data showed that P2 group had a rap-
id increase in nutritional status in the intensive 
period. It showed a strong indication that daily 
supplementation using 20 drops of 30% propolis 
in ATDs could accelerate the nutritional status re-
covery of the subjects.
Figure 4. Changes in mean body mass index differences of the subjects in 
                P0, P1 and P2 groups during intervention
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The statistical evidence of benefit from 
propolis supplementation to restore BMI was 
also reinforced by Kruskal-Wallis test and Mann-
Whitney advanced test, which showed that the 
changes in BMI in P2 and P0 groups were sig-
nificantly different from the first week until the 
24th week (p<0.05 and p<0.1) (Table 5).
Observation on the pattern of BMI chang-
es showed that the BMI recovery of P1 and P2 
groups occurred at week 4 and week 1, respec-
tively. Meanwhile, BMI of the P0 group had not 
recovered until the 24th week. It was also seen that 
intensive use of ATDs might cause a decrease in 
nutritional status (as shown from the decreased 
in BMI of P0 and P1 groups within the intensive 
treatment period). Conversely, the supplementa-
tion of 20 drops of 30% propolis alongside the 
ATDs could reduce the effect of decreased nu-
tritional status due to ATDs consumption. More-
over, it also could improve nutritional status of 
the subjects. 
In line with the results of this study, Shetty 
(2010) stated that there was an interaction be-
tween undernutrition and infection. The BMI 
data above showed that M. tuberculosis infec-
tion might decrease the nutritional status of the 
subjects through certain mechanism. The results 
of this study were also in agreement with the re-
search results of Moses et al. (2009); Tungdim 
and Kapoor (2008); Lombardo (2012); Patra et 
al. (2010), Sultan et al. (2012), and Chung-Del-
gado et al. (2014), who found that Tb patients 
significantly had lower nutritional status com-
pared to the healthy population. 
CONCLUSION
Based on the sputum smear ARB conver-
sion, the propolis supplementation groups (P1 
and P2) recovered faster than the placebo propo-
lis supplementation group (P0). Higher concen-
tration of propolis lead to faster sputum’s conver-
sion. Similarly with the changes in mean BW, in 
which higher concentration of propolis supple-
ment result in faster BW recovery. Furthermore, 
BW of P2 group had increased immediately from 
the beginning. Thus, supplementation of 20 drops 
of propolis with a concentration of 30% along 
with ATDs during the treatment are effective to 
accelerate the cure and BW recovery processes of 
pulmonary Tb patients. Considering that propolis 
is clinically proven to be able to accelerate cure 
and BW recovery of pulmonary Tb patients, it 
has a potential to be used as a supplement for na-
tional Tb control.
Table 5. Kruskal-Wallis test and Mann-Whitney advanced test on the difference in mean BMI 
                of the subjects at weeks 1, 2, 6, 8 and at the 6th month
Response
Model test 
(Kruskal-Wallis) Mann-Whitney advanced test
p Treatment p Description
BMIW1-BMI0 
difference
 
 
0.030*
 
 
P0-P1 0.769 Not significantly different
P0-P2 0.051 Significantly different at 10% level
P1-P2 0.063 Significantly different at 10% level
BMIW2-BMI0 
difference 
 
0.001*
 
 
P0-P1 0.125 Not significantly different
P0-P2 0.000 Significantly different at 5% level
P1-P2 0.037 Significantly different at 5% level
BMIW6-BMI0 
difference 
 
0.014*
 
 
P0-P1 0.482 Not significantly different
P0-P2 0.006 Significantly different at 5% level
P1-P2 0.029 Significantly different at 5% level
BMIW8-BMI0 
difference 
 
0.054**
 
 
P0-P1 0.329 Not significantly different
P0-P2 0.023 Significantly different at 5% level
P1-P2 0.123 Not significantly different
BMIW24-BMI0 
difference 
 
0.135
 
 
P0-P1 0.541 Not significantly different
P0-P2 0.063 Significantly different at 10% level
P1-P2 0.158 Not significantly different
Description: *) Significantly different at 5% level, **) Significantly different at 10% level.
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